Search results
Results from the WOW.Com Content Network
Observational longitudinal studies have further evaluated REMS T-score performance in the identification of patients at risk for fragility fracture. [1] [2] Specifically, in Adami et al., [1] a group of more than 1.500 patients has undergone both DXA and REMS scans. Afterwards, these patients have been monitored for a period up to 5 years in ...
Bone densities are often given to patients as a T score or a Z score. A T score tells the patient what their bone mineral density is in comparison to a young adult of the same gender with peak bone mineral density. A normal T score is -1.0 and above, low bone density is between -1.0 and -2.5, and osteoporosis is -2.5 and lower.
Similarly to bisphosphonates, denosumab appears to be implicated in increasing the risk of osteonecrosis of the jaw (ONJ) following extraction of teeth or oral surgical procedures but, unlike bisphosphonate, the risk declines to zero approximately 6 months after injection. [23] Invasive dental procedures should be avoided during this time.
Primary, or involuntary osteoporosis, can further be classified into Type I or Type II. [1] Type I refers to postmenopausal osteoporosis and is caused by the deficiency of estrogen. [1] While senile osteoporosis is categorized as an involuntary, Type II, and primary osteoporosis, which affects both men and women over the age of 70 years.
Zoledronic acid is used to prevent bone fractures in patients with cancers such as multiple myeloma and prostate cancer, as well as for treating osteoporosis. [10] It can also be used to treat hypercalcaemia of malignancy and can be helpful for treating pain from bone metastases.
The Osteoporosis and Bone Research Academy is the first dedicated academy for osteoporosis. It is a collaborative venture with patients at its heart, which brings together leading researchers, clinicians and academics in the field to advance scientific knowledge and work towards a cure for the condition. [12]
Teriparatide was approved for medical use in the United States in 1987. [13] [23] Teriparatide (Forteo) was approved by the FDA in November 2002, for the treatment of osteoporosis in men and postmenopausal women who are at high risk for having a fracture. [27]
The trabecular bone score is a measure of bone texture correlated with bone microarchitecture and a marker for the risk of osteoporosis. Introduced in 2008, [ 1 ] its main projected use is alongside measures of bone density in better predicting fracture risk in people with metabolic bone problems.